ワクチン市場：タイプ別、ワクチン組み合わせ、供給源、ワクチン分類、投与経路、適応症、年齢層、エンドユーザー別-2025～2030年世界予測

ワクチン市場の2024年の市場規模は837億9,000万米ドルで、2025年には901億9,000万米ドル、CAGR 7.72%で成長し、2030年には1,309億4,000万米ドルに達すると予測されています。

ワクチン産業は過去10年間、比類ない成長と変貌を遂げてきました。技術の進歩、世界の健康安全保障への関心の高まり、新興疾患への迅速な対応に対する需要の高まりが、総体的に市場を再形成してきました。今日のワクチン情勢は、画期的な科学的革新だけでなく、進化する患者のニーズやダイナミックな規制状況によっても定義されています。研究者と産業の専門家は、一昔前には考えられなかったような方法で協力し、複雑な健康課題に立ち向かうため洞察とベストプラクティスを共有しています。

この包括的なエグゼクティブサマリーでは、ワクチン研究と製造を再定義し続ける主要動向、市場の促進要因、破壊的イノベーションを調査し、その舞台を整えます。製造プロセスの改善、新しいデリバリープラットフォーム、統合されたデジタル技術が、ワクチン開発のペースをいかに加速させているかを検証しています。公衆衛生への懸念が世界の施策議論の最前線にある時代において、利害関係者は機敏な対応力を維持することが課題となっています。本レポートは、競争が激化する世界市場において、戦略的な意思決定と可能性の最大化に役立つよう、詳細な分析を提供しています。

ワクチン市場の変革

ワクチンセクタは、科学的ブレークスルー、投資の増加、戦略的再編成によって変革的な変化を経験しています。メッセンジャーRNA技術革新や迅速適応臨床検査といった最近の動向は、従来のワクチン開発手法を再定義しています。このシフトは、重要な承認を遅らせることなく安全性を確保する合理化された規制プロセスによって後押しされています。

官民はデジタル技術とデータ分析の力を活用し、研究の効率化と正確な需要予測を行っています。新たな動向としては、特定の人口統計や疾患プロファイルに対応する個別化予防接種戦略や、生産能力を強化する先進的製造技術の採用が挙げられます。国境を越えた共同研究や学際的なパートナーシップは、こうした技術革新をさらに加速させ、ワクチンの状況をこれまで以上に敏感なものにしています。このようなダイナミックな変化に伴い、産業のリーダーたちは、科学的厳密性の強化、業務効率の向上、世界の健康課題への取り組みへの揺るぎないコミットメントを原動力とするビジネス機会を最大限に活用しようとしています。

市場力学を促進する市場セグメンテーションの詳細な洞察

ワクチン市場を徹底的に調査すると、産業の多様な要素に関する貴重な洞察を提供する複雑なセグメンテーション構造が明らかになります。ワクチンタイプによるセグメンテーションでは、不活化ワクチン、弱毒化ワクチン、メッセンジャーRNAワクチン、さらにサブユニット、組み換えワクチン、多糖類ワクチン、結合型ワクチン、トキソイドワクチン、ウイルスベクタワクチンに分類されます。同様に重要なのは、1価ワクチンと多価ワクチンを区別する、ワクチンの組み合わせによるセグメンテーションです。さらに、供給源カテゴリーでヒト用ワクチンと動物用ワクチンを区別することで、より詳細な分析が可能になります。さらに、市場は予防ワクチンと治療ワクチンに分類され、予防と治療の両方のニーズに対応しています。

投与経路も重要な要素であり、筋肉内、鼻腔内、経口、皮下投与が含まれ、適応症による区分では感染症と非感染症に分けられます。感染症は、肝炎、ヒトパピローマウイルス、インフルエンザ、麻疹、髄膜炎菌性疾患、百日咳、肺炎球菌性疾患、狂犬病、ロタウイルス、破傷風、水痘などの疾患にさらに細分化されており、特に注目に値します。一方、非感染性疾患では、自己免疫疾患やがんワクチンなどのセグメントが注目されます。これらを補完するものとして、成人、高齢者、小児（後者はさらに乳幼児に分けられる）を区別する人口統計学的洞察や、学術・研究機関、病院クリニック、予防接種センターなどを網羅するエンドユーザー分類があります。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 感染症の蔓延により、ワクチンの必要性が高まっている
    • 世界中でワクチン接種プログラムを支援する政府の取り組みや施策が拡大している
    • ソーシャルメディアとデジタルプラットフォームは、ワクチンの利点に関する認識と教育を拡大
  • 抑制要因
    • ワクチンに関連する高い開発と配布コスト
  • 機会
    • ワクチンの生産と流通における技術の進歩
    • 先進的なワクチン製剤の研究開発活動への投資増加
  • 課題
    • ワクチン承認のための複雑で時間のかかる規制状況を乗り越える
• 市場セグメンテーション分析
  • タイプ：メッセンジャーRNAワクチンは高い有効性があるため、非常に重要
  • エンドユーザー：緊急公衆衛生対応のために、病院やクリニック全体でワクチンの採用が増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 ワクチン市場：タイプ別

• イントロダクション
• 不活化されたワクチン
• 生弱毒化ワクチン
• メッセンジャーRNAワクチン
• サブユニット、組み換え、多糖類、コンジュゲートワクチン
• トキソイドワクチン
• ウイルスベクタワクチン

第7章 ワクチン市場：ワクチン分類別

• イントロダクション
• 一価ワクチン
• 多価ワクチン

第8章 ワクチン市場：供給源別

• イントロダクション
• 人間用ワクチン
• 獣医療ワクチン

第9章 ワクチン市場ワクチン分類別

• イントロダクション
• 予防ワクチン
• 治療ワクチン

第10章 ワクチン市場：投与経路別

• イントロダクション
• 筋肉内
• 鼻腔内
• 経口
• 皮下

第11章 ワクチン市場：適応症別

• イントロダクション
• 感染症
  • 肝炎
  • ヒトパピローマウイルス
  • インフルエンザ
  • 麻疹
  • 髄膜炎菌感染症
  • 百日咳
  • 肺炎球菌感染症
  • 狂犬病
  • ロタウイルス
  • 破傷風
  • 水痘
• 非感染性疾患
  • 自己免疫疾患
  • がんワクチン

第12章 ワクチン市場：年齢層別

• イントロダクション
• 成人
• 高齢者
• 小児
  • 乳児
  • 幼児

第13章 ワクチン市場：エンドユーザー別

• イントロダクション
• 学術研究機関
• 病院とクリニック
• ワクチン接種センター

第14章 南北アメリカのワクチン市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第15章 アジア太平洋のワクチン市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第16章 欧州・中東・アフリカのワクチン市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第17章 競合情勢

• 市場シェア分析、2024年
• FPNVポジショニングマトリックス、2024年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bavarian Nordic A/S
• Bharat BIoTech Ltd.
• Biological E. Limited
• BioNTech SE
• Blue Lake BIoTechnology
• Capricor Therapeutics, Inc.
• Chongqing Zhifei Biological Products Co., Ltd.
• CSL Limited
• CureVac N.V.
• Daiichi Sankyo Company, Limited.
• Gennova Biopharmaceuticals Limited
• GlaxoSmithKline PLC
• Haffkine Bio-Pharmaceutical Corporation Ltd
• Incepta Pharmaceuticals Ltd.
• Inovio Pharmaceuticals, Inc.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Moderna, Inc.
• Novavax, Inc.
• Pfizer Inc.
• Sanofi S.A.
• Serum Institute of India Pvt. Ltd.
• Sinovac BIoTech Ltd.
• Takeda Pharmaceutical Company Limited
• VBI Vaccines Inc.
• Versatope Therapeutics
• Zydus Lifesciences Limited

LIST OF FIGURES

• FIGURE 1. VACCINES MARKET MULTI-CURRENCY
• FIGURE 2. VACCINES MARKET MULTI-LANGUAGE
• FIGURE 3. VACCINES MARKET RESEARCH PROCESS
• FIGURE 4. VACCINES MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL VACCINES MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL VACCINES MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL VACCINES MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
• FIGURE 19. GLOBAL VACCINES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
• FIGURE 21. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. GLOBAL VACCINES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 23. GLOBAL VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 27. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 28. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 29. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 30. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 31. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 32. VACCINES MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 33. VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. VACCINES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. VACCINES MARKET DYNAMICS
• TABLE 7. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL VACCINES MARKET SIZE, BY LIVE-ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL VACCINES MARKET SIZE, BY MESSENGER RNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, & CONJUGATE VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL VACCINES MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL VACCINES MARKET SIZE, BY MONO-VALENT VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL VACCINES MARKET SIZE, BY MULTI-VALENT VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL VACCINES MARKET SIZE, BY HUMAN VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL VACCINES MARKET SIZE, BY VETERINARY VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL VACCINES MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL VACCINES MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL VACCINES MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL VACCINES MARKET SIZE, BY HUMAN PAPILLOMAVIRUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL VACCINES MARKET SIZE, BY MEASLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL VACCINES MARKET SIZE, BY MENINGOCOCCAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL VACCINES MARKET SIZE, BY PERTUSSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL VACCINES MARKET SIZE, BY PNEUMOCOCCAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL VACCINES MARKET SIZE, BY RABIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL VACCINES MARKET SIZE, BY ROTAVIRUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL VACCINES MARKET SIZE, BY TETANUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL VACCINES MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL VACCINES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 49. GLOBAL VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 50. GLOBAL VACCINES MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 51. GLOBAL VACCINES MARKET SIZE, BY TODDLERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 52. GLOBAL VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 53. GLOBAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 54. GLOBAL VACCINES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 55. GLOBAL VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 56. GLOBAL VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 57. AMERICAS VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. AMERICAS VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 59. AMERICAS VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 60. AMERICAS VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 61. AMERICAS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. AMERICAS VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. AMERICAS VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 64. AMERICAS VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 65. AMERICAS VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 66. AMERICAS VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 67. AMERICAS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 68. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 69. ARGENTINA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. ARGENTINA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 71. ARGENTINA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 72. ARGENTINA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 73. ARGENTINA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. ARGENTINA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. ARGENTINA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 76. ARGENTINA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 77. ARGENTINA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 78. ARGENTINA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 79. ARGENTINA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 80. BRAZIL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. BRAZIL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 82. BRAZIL VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 83. BRAZIL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 84. BRAZIL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 85. BRAZIL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 86. BRAZIL VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 87. BRAZIL VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 88. BRAZIL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 89. BRAZIL VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 90. BRAZIL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 91. CANADA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. CANADA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 93. CANADA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 94. CANADA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 95. CANADA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 96. CANADA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. CANADA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 98. CANADA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 99. CANADA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 100. CANADA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 101. CANADA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 102. MEXICO VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. MEXICO VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 104. MEXICO VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 105. MEXICO VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 106. MEXICO VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 107. MEXICO VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 108. MEXICO VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 109. MEXICO VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 110. MEXICO VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 111. MEXICO VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 112. MEXICO VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 113. UNITED STATES VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. UNITED STATES VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 115. UNITED STATES VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 116. UNITED STATES VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 117. UNITED STATES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 118. UNITED STATES VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 119. UNITED STATES VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 120. UNITED STATES VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 121. UNITED STATES VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 122. UNITED STATES VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 123. UNITED STATES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 124. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 125. ASIA-PACIFIC VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. ASIA-PACIFIC VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 127. ASIA-PACIFIC VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 128. ASIA-PACIFIC VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 129. ASIA-PACIFIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 130. ASIA-PACIFIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 131. ASIA-PACIFIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 132. ASIA-PACIFIC VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 133. ASIA-PACIFIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 134. ASIA-PACIFIC VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 135. ASIA-PACIFIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 136. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 137. AUSTRALIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. AUSTRALIA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 139. AUSTRALIA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 140. AUSTRALIA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 141. AUSTRALIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 142. AUSTRALIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 143. AUSTRALIA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 144. AUSTRALIA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 145. AUSTRALIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 146. AUSTRALIA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 147. AUSTRALIA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 148. CHINA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 149. CHINA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 150. CHINA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 151. CHINA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 152. CHINA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 153. CHINA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 154. CHINA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 155. CHINA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 156. CHINA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 157. CHINA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 158. CHINA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 159. INDIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 160. INDIA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 161. INDIA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 162. INDIA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 163. INDIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 164. INDIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 165. INDIA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 166. INDIA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 167. INDIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 168. INDIA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 169. INDIA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 170. INDONESIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 171. INDONESIA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 172. INDONESIA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 173. INDONESIA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 174. INDONESIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 175. INDONESIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 176. INDONESIA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 177. INDONESIA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 178. INDONESIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 179. INDONESIA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 180. INDONESIA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 181. JAPAN VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 182. JAPAN VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 183. JAPAN VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 184. JAPAN VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 185. JAPAN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 186. JAPAN VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 187. JAPAN VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 188. JAPAN VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 189. JAPAN VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 190. JAPAN VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 191. JAPAN VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 192. MALAYSIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 193. MALAYSIA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 194. MALAYSIA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 195. MALAYSIA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 196. MALAYSIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 197. MALAYSIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 198. MALAYSIA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 199. MALAYSIA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 200. MALAYSIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 201. MALAYSIA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 202. MALAYSIA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 203. PHILIPPINES VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 204. PHILIPPINES VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 205. PHILIPPINES VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 206. PHILIPPINES VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 207. PHILIPPINES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 208. PHILIPPINES VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 209. PHILIPPINES VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 210. PHILIPPINES VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 211. PHILIPPINES VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 212. PHILIPPINES VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 213. PHILIPPINES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 214. SINGAPORE VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 215. SINGAPORE VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 216. SINGAPORE VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 217. SINGAPORE VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 218. SINGAPORE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 219. SINGAPORE VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 220. SINGAPORE VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 221. SINGAPORE VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 222. SINGAPORE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 223. SINGAPORE VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 224. SINGAPORE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 225. SOUTH KOREA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 226. SOUTH KOREA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 227. SOUTH KOREA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 228. SOUTH KOREA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 229. SOUTH KOREA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 230. SOUTH KOREA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 231. SOUTH KOREA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 232. SOUTH KOREA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 233. SOUTH KOREA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 234. SOUTH KOREA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 235. SOUTH KOREA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 236. TAIWAN VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 237. TAIWAN VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 238. TAIWAN VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 239. TAIWAN VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 240. TAIWAN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 241. TAIWAN VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 242. TAIWAN VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 243. TAIWAN VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 244. TAIWAN VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 245. TAIWAN VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 246. TAIWAN VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 247. THAILAND VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 248. THAILAND VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 249. THAILAND VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 250. THAILAND VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 251. THAILAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 252. THAILAND VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 253. THAILAND VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 254. THAILAND VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 255. THAILAND VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 256. THAILAND VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 257. THAILAND VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 258. VIETNAM VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 259. VIETNAM VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 260. VIETNAM VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 261. VIETNAM VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 262. VIETNAM VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 263. VIETNAM VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 264. VIETNAM VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 265. VIETNAM VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 266. VIETNAM VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 267. VIETNAM VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 268. VIETNAM VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 269. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 270. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 271. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 272. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 273. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 274. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 275. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 276. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 277. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 278. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 279. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 280. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 281. DENMARK VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 282. DENMARK VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 283. DENMARK VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 284. DENMARK VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 285. DENMARK VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 286. DENMARK VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 287. DENMARK VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 288. DENMARK VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 289. DENMARK VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 290. DENMARK VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 291. DENMARK VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 292. EGYPT VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 293. EGYPT VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 294. EGYPT VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 295. EGYPT VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 296. EGYPT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 297. EGYPT VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 298. EGYPT VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 299. EGYPT VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 300. EGYPT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 301. EGYPT VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 302. EGYPT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 303. FINLAND VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 304. FINLAND VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 305. FINLAND VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 306. FINLAND VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 307. FINLAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 308. FINLAND VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 309. FINLAND VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 310. FINLAND VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 311. FINLAND VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 312. FINLAND VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 313. FINLAND VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 314. FRANCE VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 315. FRANCE VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 316. FRANCE VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 317. FRANCE VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 318. FRANCE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 319. FRANCE VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 320. FRANCE VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 321. FRANCE VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 322. FRANCE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 323. FRANCE VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 324. FRANCE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 325. GERMANY VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 326. GERMANY VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 327. GERMANY VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 328. GERMANY VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 329. GERMANY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 330. GERMANY VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 331. GERMANY VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 332. GERMANY VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 333. GERMANY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 334. GERMANY VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 335. GERMANY VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 336. ISRAEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 337. ISRAEL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 338. ISRAEL VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 339. ISRAEL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 340. ISRAEL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 341. ISRAEL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 342. ISRAEL VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 343. ISRAEL VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 344. ISRAEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 345. ISRAEL VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 346. ISRAEL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 347. ITALY VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 348. ITALY VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 349. ITALY VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 350. ITALY VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 351. ITALY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 352. ITALY VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 353. ITALY VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 354. ITALY VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 355. ITALY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 356. ITALY VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 357. ITALY VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 358. NETHERLANDS VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 359. NETHERLANDS VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 360. NETHERLANDS VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 361. NETHERLANDS VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 362. NETHERLANDS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 363. NETHERLANDS VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 364. NETHERLANDS VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 365. NETHERLANDS VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 366. NETHERLANDS VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 367. NETHERLANDS VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 368. NETHERLANDS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 369. NIGERIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 370. NIGERIA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 371. NIGERIA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 372. NIGERIA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 373. NIGERIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 374. NIGERIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 375. NIGERIA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 376. NIGERIA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 377. NIGERIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 378. NIGERIA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
• TABLE 379. NIGERIA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 380. NORWAY VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 381. NORWAY VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
• TABLE 382. NORWAY VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 383. NORWAY VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 384. NORWAY VACCINES MAR

The Vaccines Market was valued at USD 83.79 billion in 2024 and is projected to grow to USD 90.19 billion in 2025, with a CAGR of 7.72%, reaching USD 130.94 billion by 2030.

The vaccine industry has witnessed unparalleled growth and transformation over the past decade. Advances in technology, a heightened focus on global health security, and an increased demand for rapid responses to emerging diseases have collectively reshaped the market. Today's vaccine landscape is not only defined by breakthrough scientific innovations but also by evolving patient needs and dynamic regulatory environments. Researchers and industry experts are working together in ways that were unthinkable a generation ago, sharing insights and best practices to combat complex health challenges.

This comprehensive executive summary sets the stage by exploring key trends, market drivers, and disruptive innovations that continue to redefine vaccine research and production. It examines how improved manufacturing processes, novel delivery platforms, and integrated digital technologies have accelerated the pace of vaccine development. In an age where public health concerns are at the forefront of global policy discussions, stakeholders are challenged to remain agile and responsive. This report provides an in-depth analysis designed to inform strategic decision-making and maximize potential in an increasingly competitive global marketplace.

Transformative Shifts in the Vaccine Landscape

The vaccine sector is experiencing transformative shifts driven by scientific breakthroughs, increased investments, and strategic realignments. Recent developments, such as messenger RNA innovations and rapid adaptive clinical trials, have redefined traditional vaccine development practices. This shift is bolstered by streamlined regulatory processes that ensure safety without delaying critical approvals.

Public and private sectors are harnessing the power of digital technologies and data analytics to improve research efficiency and forecast demand accurately. Emerging trends include a focus on personalized immunization strategies that cater to specific demographics and disease profiles, as well as the adoption of advanced manufacturing techniques that bolster production capacities. Collaborative research across international borders and interdisciplinary partnerships has further amplified these innovations, making the vaccine landscape more responsive than ever. With these dynamic changes, industry leaders are set to capitalize on opportunities driven by enhanced scientific rigor, operational efficiencies, and an unwavering commitment to addressing global health challenges.

In-depth Segmentation Insights Driving Market Dynamics

A thorough examination of the vaccine market reveals a complex segmentation structure that provides valuable insights into the diverse elements of the industry. The segmentation based on type dissects the market into inactivated vaccines, live-attenuated vaccines, messenger RNA vaccines, as well as subunit, recombinant, polysaccharide, conjugate, toxoid, and viral vector vaccines. Equally critical is the segmentation based on vaccine combination, which distinguishes between mono-valent and multi-valent vaccines. A further layer of analysis is provided by distinguishing between human and veterinary vaccines under the source category. Moreover, the market is methodically classified into preventive vaccines and therapeutic vaccines, addressing both prophylactic and treatment-oriented needs.

The route of administration is another key factor, covering intramuscular, intranasal, oral, and subcutaneous methods, while the indication-based segmentation divides the market into infectious diseases and non-infectious diseases. Infectious diseases merit special attention, as they are further subdivided into conditions such as hepatitis, human papillomavirus, influenza, measles, meningococcal disease, pertussis, pneumococcal disease, rabies, rotavirus, tetanus, and varicella. Meanwhile, non-infectious diseases highlight segments like autoimmune diseases and cancer vaccines. Complementing these are demographic insights that differentiate between adult, geriatric, and pediatric populations-the latter further broken down into infants and toddlers-and end user classifications that encompass academic and research institutes, hospitals and clinics, as well as vaccination centers.

Based on Type, market is studied across Inactivated Vaccines, Live-Attenuated Vaccines, Messenger RNA Vaccines, Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines, Toxoid Vaccines, and Viral Vector Vaccines.

Based on Vaccine Combination, market is studied across Mono-Valent Vaccines and Multi-Valent Vaccines.

Based on Source, market is studied across Human Vaccines and Veterinary Vaccines.

Based on Vaccine Classification, market is studied across Preventive Vaccines and Therapeutic Vaccines.

Based on Route of Administration, market is studied across Intramuscular, Intranasal, Oral, and Subcutaneous.

Based on Indication, market is studied across Infectious Diseases and Non-Infectious Diseases. The Infectious Diseases is further studied across Hepatitis, Human Papillomavirus, Influenza, Measles, Meningococcal Disease, Pertussis, Pneumococcal Disease, Rabies, Rotavirus, Tetanus, and Varicella. The Non-Infectious Diseases is further studied across Autoimmune Diseases and Cancer Vaccines.

Based on Age Group, market is studied across Adult, Geriatric, and Pediatric. The Pediatric is further studied across Infants and Toddlers.

Based on End User, market is studied across Academic & Research Institutes, Hospitals & Clinics, and Vaccination Centers.

Regional Market Perspectives and Emerging Trends

The global vaccine market exhibits distinct variations across regions, each characterized by unique challenges and opportunities that contribute to a dynamic industry landscape. In the Americas, the market benefits from a mature infrastructure supported by advanced research facilities and a history of successful immunization programs. By contrast, in regions spanning Europe, the Middle East, and Africa, a blend of established healthcare systems and rapidly emerging markets fosters both continuity in research and innovation in deployment strategies.

The Asia-Pacific region stands out as a burgeoning powerhouse, where strong governmental support, increasing investments in healthcare infrastructure, and accelerating public-private partnerships are driving exponential growth. These regional variations compel stakeholders to tailor their strategies to local market conditions while remaining informed of global trends. Assessing regional insights ensures that emerging opportunities are comprehensively addressed, whether by leveraging the technological prowess of the Americas, the progressive reforms in Europe, the Middle East, and Africa, or the dynamic expansion seen in the Asia-Pacific region.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Players Shaping the Future of Vaccines

The competitive landscape in the vaccine market is defined by a host of influential companies that drive innovation and market growth on a global scale. Industry leaders such as Abbott Laboratories, Astellas Pharma Inc., AstraZeneca PLC, and Bavarian Nordic A/S have long been recognized for setting high standards in safety and efficacy. Equally significant are Bharat Biotech Ltd. and Biological E. Limited, whose cost-effective and scalable vaccine solutions have opened new avenues in emerging markets. Advanced biotech firms like BioNTech SE and Blue Lake Biotechnology are at the forefront of developing cutting-edge messenger RNA platforms, while Capricor Therapeutics, Inc., Chongqing Zhifei Biological Products Co., Ltd., CSL Limited, and CureVac N.V. are rapidly gaining ground in research and development.

The landscape is further enhanced by the contributions of Daiichi Sankyo Company, Limited., Gennova Biopharmaceuticals Limited, and GlaxoSmithKline PLC, alongside renowned institutions such as Haffkine Bio-Pharmaceutical Corporation Ltd, Incepta Pharmaceuticals Ltd., Inovio Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., and Merck & Co., Inc. Innovative companies like Moderna, Inc., Novavax, Inc., Pfizer Inc., Sanofi S.A., and Serum Institute of India Pvt. Ltd. also play pivotal roles, complemented by Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, VBI Vaccines Inc., Versatope Therapeutics, and Zydus Lifesciences Limited. Collectively, these organizations harness sophisticated technologies, cutting-edge research, and expansive distribution networks to drive market evolution and deliver impactful health solutions worldwide.

The report delves into recent significant developments in the Vaccines Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma Inc., AstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech Ltd., Biological E. Limited, BioNTech SE, Blue Lake Biotechnology, Capricor Therapeutics, Inc., Chongqing Zhifei Biological Products Co., Ltd., CSL Limited, CureVac N.V., Daiichi Sankyo Company, Limited., Gennova Biopharmaceuticals Limited, GlaxoSmithKline PLC, Haffkine Bio-Pharmaceutical Corporation Ltd, Incepta Pharmaceuticals Ltd., Inovio Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Moderna, Inc., Novavax, Inc., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, VBI Vaccines Inc., Versatope Therapeutics, and Zydus Lifesciences Limited. Actionable Recommendations for Industry Leaders

Industry leaders operating in the vaccine sector are encouraged to adopt a proactive approach that balances innovation with operational excellence. To stay competitive, it is essential to invest in modern research and development infrastructure and establish cross-functional partnerships that can accelerate the translation of scientific discovery into market-ready solutions. Embracing digital transformation-by integrating advanced data analytics and real-time monitoring systems-will enhance decision-making processes and facilitate refined market insights.

Furthermore, leaders should prioritize regulatory agility by actively engaging with policy makers to streamline approval mechanisms without compromising stringent safety standards. Strengthening supply chain processes and diversifying manufacturing capabilities will hedge against unforeseen disruptions while ensuring consistent product availability. Collaborative efforts with academic institutions, hospitals, and vaccination centers can further solidify market presence and expand outreach. By cultivating a culture of continuous improvement, transparent communication, and robust risk management, industry stakeholders can not only mitigate emerging challenges but also harness new opportunities in an evolving global landscape.

Conclusive Reflections on the Vaccine Industry

The vaccine market is at a pivotal juncture, marked by rapid scientific advancements and ever-evolving market demands. This executive summary has illustrated how the nuanced segmentation across vaccine type, combination, source, classification, route of administration, and indication provides a detailed framework for understanding market dynamics. In addition, demographic factors and end user insights enrich the overall analysis, offering a multi-dimensional view of the challenges and opportunities that lie ahead.

Regional insights reveal that mature markets, emerging economies, and dynamic growth regions each offer unique prospects that must be strategically leveraged. The sustained innovation and agility demonstrated by key industry players underlie a resilient ecosystem that is capable of responding to both current and future public health needs. Ultimately, the synthesis of these insights reinforces the importance of informed decision-making and strategic investments, empowering stakeholders to navigate an increasingly competitive and complex landscape with confidence and precision.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of infectious diseases raising the need for vaccines
    • 5.1.1.2. Growing government initiatives and policies supporting vaccination programs around the world
    • 5.1.1.3. Social media and digital platforms amplifying awareness and education about the benefits of vaccines
  • 5.1.2. Restraints
    • 5.1.2.1. High development and distribution costs associated with vaccines
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in vaccine production and distribution
    • 5.1.3.2. Rising investments in research and development activities for advanced vaccine formulation
  • 5.1.4. Challenges
    • 5.1.4.1. Navigating the complex and time-consuming regulatory landscape for vaccine approval
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Critical need for messenger RNA vaccines due to their high effectiveness
  • 5.2.2. End user: Rising adoption of vaccines across hospitals & clinics for emergency public health responses.
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Vaccines Market, by Type

• 6.1. Introduction
• 6.2. Inactivated Vaccines
• 6.3. Live-Attenuated Vaccines
• 6.4. Messenger RNA Vaccines
• 6.5. Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines
• 6.6. Toxoid Vaccines
• 6.7. Viral Vector Vaccines

7. Vaccines Market, by Vaccine Combination

• 7.1. Introduction
• 7.2. Mono-Valent Vaccines
• 7.3. Multi-Valent Vaccines

8. Vaccines Market, by Source

• 8.1. Introduction
• 8.2. Human Vaccines
• 8.3. Veterinary Vaccines

9. Vaccines Market, by Vaccine Classification

• 9.1. Introduction
• 9.2. Preventive Vaccines
• 9.3. Therapeutic Vaccines

10. Vaccines Market, by Route of Administration

• 10.1. Introduction
• 10.2. Intramuscular
• 10.3. Intranasal
• 10.4. Oral
• 10.5. Subcutaneous

11. Vaccines Market, by Indication

• 11.1. Introduction
• 11.2. Infectious Diseases
  • 11.2.1. Hepatitis
  • 11.2.2. Human Papillomavirus
  • 11.2.3. Influenza
  • 11.2.4. Measles
  • 11.2.5. Meningococcal Disease
  • 11.2.6. Pertussis
  • 11.2.7. Pneumococcal Disease
  • 11.2.8. Rabies
  • 11.2.9. Rotavirus
  • 11.2.10. Tetanus
  • 11.2.11. Varicella
• 11.3. Non-Infectious Diseases
  • 11.3.1. Autoimmune Diseases
  • 11.3.2. Cancer Vaccines

12. Vaccines Market, by Age Group

• 12.1. Introduction
• 12.2. Adult
• 12.3. Geriatric
• 12.4. Pediatric
  • 12.4.1. Infants
  • 12.4.2. Toddlers

13. Vaccines Market, by End User

• 13.1. Introduction
• 13.2. Academic & Research Institutes
• 13.3. Hospitals & Clinics
• 13.4. Vaccination Centers

14. Americas Vaccines Market

• 14.1. Introduction
• 14.2. Argentina
• 14.3. Brazil
• 14.4. Canada
• 14.5. Mexico
• 14.6. United States

15. Asia-Pacific Vaccines Market

• 15.1. Introduction
• 15.2. Australia
• 15.3. China
• 15.4. India
• 15.5. Indonesia
• 15.6. Japan
• 15.7. Malaysia
• 15.8. Philippines
• 15.9. Singapore
• 15.10. South Korea
• 15.11. Taiwan
• 15.12. Thailand
• 15.13. Vietnam

16. Europe, Middle East & Africa Vaccines Market

• 16.1. Introduction
• 16.2. Denmark
• 16.3. Egypt
• 16.4. Finland
• 16.5. France
• 16.6. Germany
• 16.7. Israel
• 16.8. Italy
• 16.9. Netherlands
• 16.10. Nigeria
• 16.11. Norway
• 16.12. Poland
• 16.13. Qatar
• 16.14. Russia
• 16.15. Saudi Arabia
• 16.16. South Africa
• 16.17. Spain
• 16.18. Sweden
• 16.19. Switzerland
• 16.20. Turkey
• 16.21. United Arab Emirates
• 16.22. United Kingdom

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Scenario Analysis
  • 17.3.1. Mankind Pharma acquires Bharat Serums and Vaccines (BSV) for strategic expansion in Women's Health and Fertility market
  • 17.3.2. Sanofi and Novavax partner to co-commercialize new COVID-19 vaccine and develop flu-COVID combo shot
  • 17.3.3. CureVac and MD Anderson team up to develop mRNA-based cancer vaccines, paving the way for advanced cancer treatments
  • 17.3.4. Bavarian Nordic launches mpox vaccine in the U.S., boosting preventive healthcare and market innovation
  • 17.3.5. Bharat Biotech and Bilthoven Biologicals unite to boost global polio eradication efforts with enhanced OPV production
  • 17.3.6. Takeda forms partnership to boost global access to dengue vaccine, targeting hard-hit regions
  • 17.3.7. AstraZeneca bolsters vaccine capabilities by acquiring biotechnology firm Icosavax
  • 17.3.8. Serum Institute of India Partners with CEPI to increase global vaccine accessibility during epidemics
  • 17.3.9. GSK partners with Zhifei to exclusively distribute shingles vaccine Shingrix in China, aiming to enhance public health and vaccine access
  • 17.3.10. Janssen and Sanofi join forces to develop vaccine program to address unmet medical needs
• 17.4. Strategy Analysis & Recommendation
  • 17.4.1. AstraZeneca PLC
  • 17.4.2. Pfizer Inc.
  • 17.4.3. GlaxoSmithKline PLC
  • 17.4.4. Merck & Co., Inc.
  • 17.4.5. Sanofi S.A.

Companies Mentioned

• 1. Abbott Laboratories
• 2. Astellas Pharma Inc.
• 3. AstraZeneca PLC
• 4. Bavarian Nordic A/S
• 5. Bharat Biotech Ltd.
• 6. Biological E. Limited
• 7. BioNTech SE
• 8. Blue Lake Biotechnology
• 9. Capricor Therapeutics, Inc.
• 10. Chongqing Zhifei Biological Products Co., Ltd.
• 11. CSL Limited
• 12. CureVac N.V.
• 13. Daiichi Sankyo Company, Limited.
• 14. Gennova Biopharmaceuticals Limited
• 15. GlaxoSmithKline PLC
• 16. Haffkine Bio-Pharmaceutical Corporation Ltd
• 17. Incepta Pharmaceuticals Ltd.
• 18. Inovio Pharmaceuticals, Inc.
• 19. Johnson & Johnson Services, Inc.
• 20. Merck & Co., Inc.
• 21. Moderna, Inc.
• 22. Novavax, Inc.
• 23. Pfizer Inc.
• 24. Sanofi S.A.
• 25. Serum Institute of India Pvt. Ltd.
• 26. Sinovac Biotech Ltd.
• 27. Takeda Pharmaceutical Company Limited
• 28. VBI Vaccines Inc.
• 29. Versatope Therapeutics
• 30. Zydus Lifesciences Limited